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Neovascularisation is a key step in tumour growth and establishment of distant metastases. We have recently demonstrated
that the thienopyridine SR 25989 an enantiomer of the anti-aggregant clopidogrel (Plavix
1) lacking anti-aggregant activity,
inhibits endothelial cell proliferation in vitro by increasing the expression of endogenous thrombospondin-1, a natural potent
inhibitor of angiogenesis. The anti-angiogenic effect of SR 25989 was further assessed in vitro in a quantitative assay of
angiogenesis comprising a fragment of rat aorta embedded in a ﬁbrin gel and in vivo in a pulmonary metastatic model using
C57BL/6 mice inoculated in the foot pad with the highly metastatic melanoma cell line B16 F10. SR 25989 induced a dose
dependent inhibition of spontaneous microvessel development in vitro reaching half maximal inhibition at around less than
50 mM and caused platelet derived growth factor induced angiogenesis to regress as a function of thienopyridine
concentration. In vivo, SR 25989 did not alter signiﬁcantly the growth rate of the primary tumour in the foot pad and did not
inhibit development of inguinal nodes which appeared after amputation. However, the number and size of lung metastases
were reduced in treated animals when examined at the time of sacriﬁce. In addition, the few metastases over 1 mm
3 did not
show any neovascularisation, as conﬁrmed by negative von Willebrand immunostaining and in contrast to intense
vascularisation seen in metastases developed by control mice. These results conﬁrm that SR 25989 possesses potent anti-
angiogenic properties and is able to inhibit metastatic dissemination and growth. The lack of effect on the primary tumour and
inguinal nodes illustrates the complexity of the mechanisms involved in tumoural neo-angiogenesis and points out the
possibility for distinct processes leading to neovascularisation in primary tumour as opposed to metastases.
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For three decades angiogenesis has been recognised as a key step in
tumour growth and metastasis development (Folkman, 1995a,b).
The great cellular and genetic diversity of solid tumours is respon-
sible for the wide disparity of their responses towards chemical/
radiotherapeutic treatments. One common element among their
characteristics is the tumour vasculature which shares identical
features throughout the tumoral tissues and which is different from
the vasculature of normal tissues. The tumour vasculature has an
immature endothelium and forms an abnormal network of leaky
vessels with chaotic ﬂow (Denekamp et al, 1998). Below a critical
size of 1–2 mm
3 metastases are supposed not to need to be vascu-
larised for their nutritive supply (Folkman, 1990). However some
tumours can grow above this size without inducing angiogenesis
by using some alternative strategies such as vessel cooption (Holash
et al, 1999) or tumour cells forming their own channels (Barinaga,
1999; Maniotis et al, 1999). Despite these particularities, it appears
that tumour angiogenesis now represents a promising therapeutic
target for the treatment of cancer (Deplanque and Harris, 2000;
Kerbel, 2000; Liekens et al, 2001). Among the abundance of mole-
cules to which an angiostatic or anti-angiogenic property has been
assigned, some of them have today reached the stage of the clinical
assay. Although the mechanisms of these molecules are way from
being all elucidated, several strategies have been drawn: (i) inhibi-
tion of signalling pathways – by targeting tyrosine kinase receptors
involving growth factors such as basic ﬁbroblast growth factor
(bFGF), platelet derived growth factor (PDGF) and vascular
endothelial growth factor (VEGF) which are strong inducers of
angiogenesis (Laird et al, 2000; Pegram and Slamon, 2000), – by
inhibition of the growth factors themselves (Pepper et al, 1996;
Lee et al, 2000), – or by inhibiting adhesion molecule receptors
like the integrin av b3 which is essentially expressed in growing
capillaries (Brooks et al, 1994; Gutheil et al, 2000); (ii) inhibition
of tumour neovascularisation by means of endogenous polypeptide
fragments or proteins having anti-angiogenic or angiostatic proper-
ties: molecules such as angiostatin, an internal fragment of
plasminogen (O’Reilly et al, 1994), endostatin, a fragment of
collagen XVIII (O’Reilly et al, 1997), platelet factor 4 (PF4),
(Maione et al, 1990), interferons (Ezekowitz et al, 1992) and
thrombospondin-1 (TSP-1), a matricellular protein (Bornstein,
1995) appear among these molecules (reviewed in Sage, 1997;
Carmeliet and Jain, 2000; Kerbel, 2000); (iii) reassessment of mole-
cules which were not originally developed as anti-tumour
angiogenesis drugs but for which anti-angiogenic properties were
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www.bjcancer.com‘accidentally’ discovered. Thalidomide, a synthetic sedative, micro-
tubule-affecting drugs such as taxanes or low doses of
methotrexate, are among this type of ‘accidental’ anti-angiogenic
molecules presently tested in clinical assays as adjuvants of anti-
tumour therapy (reviewed in Kerbel et al, 2000); (iv) ﬁnally one
possible strategy could consist in inducing the expression of consti-
tutive endogenous anti-angiogenic molecules.
We have recently demonstrated that a molecule belonging to
the thienopyridine family, SR 25989 inhibits constitutive and
aFGF or bFGF driven endothelial cell proliferation and migration
in a wound healing model (Klein-Soyer et al, 1994). The
decrease in cell proliferation is correlated to an upregulation of
the expression of TSP-1 (Klein-Soyer et al, 1997). Furthermore,
preliminary experiments using ﬁbrin gel chambers implanted in
the dorsal subcutaneous space of the rat demonstrated that SR
25989 inhibits neovascularisation in vivo (Cazenave and Herbert,
1992; Toti et al, 2001). Consequently, these antiangiogenic effects
of SR 25989 were further assessed and we report presently the
results obtained both in vitro in a quantitative assay of angio-
genesis using the model developed by Nicosia and Ottinetti
(1990) and in vivo in a murine pulmonary metastatis model
using C57BL/6 mice inoculated with the highly metastatic mela-
noma cell line B16 F10.
MATERIALS AND METHODS
Animals, cells and materials
Male Wistar rats weighing between 200 and 250 g and male mice
C57BL/6 weighing between 22 and 25 g, both kinds pathogen free,
were obtained from Charles River (St Aubin, Les Elbeufs, France).
Animal care and experimentation were in accordance with the
institutional guidelines from the Ministe `re Franc ¸ais de l’Agricul-
ture and The UKCCCR Guidelines (1998) for the welfare of
animals in experimental neoplasia. All animal were fed a diet of
animal chow and water ad libitum. The animals were anaesthe-
tised with intramuscular xylasin (8 mg kg
71) (Rompun
1, Bayer
Leverkusen, Germany) and ketamin (40 mg kg
71) (Ketalar
1,
Substantia Division Sante ￿, Courbevoie, France). The highly meta-
static B16 F10 mouse melanoma cell line (Fidler, 1973) was a
generous gift from Dr IJ Fidler. Agarose type VI A, rat ﬁbrinogen
(fraction I, 490% clottable), e-aminocaproic acid, magnesium
sulphate (MgSO4, cell culture tested) and calcium chloride
(CaCl2) were from Sigma (St Louis, MO, USA). Cell culture
medium (DMEM/HAM F12, with 15 mM HEPES; RPMI 1640)
Hank’s balanced salt solution, L-glutamine, antibiotics (penicillin,
streptomycin), fungizone and foetal calf serum (myoclone plus,
virus and mycoplasma screened) (FCS) were from Gibco (Paisley,
UK). Petri culture dishes, six well dishes and culture ﬂasks (tissue
culture grade) were from Falcon, Becton Dickinson Company
(Lincoln Park, NJ, USA). Human serum albumin (HSA) solution
was from the Etablissement de Transfusion Sanguine de Stras-
bourg, France. Human a-thrombin was prepared in the
laboratory according to published methods (Ngai and Chang,
1991) and platelet derived growth factor (PDGF) was from
R&D systems (Minneapolis, MN, USA). Recombinant hirudin
and the thienopyridine, SR 25989, were a gift from Sanoﬁ
Recherche (Toulouse, France). Anti-human von Willebrand factor
(vWf) antibody, immunoglobulin fraction, and monoclonal mouse
anti-human a-smooth muscle actin (a-SMA) antibody (clone1A4;
IgG2ak) were from Dako A/S, (Glostrub, Denmark). Polyclonal
rabbit immunoglobulin fraction was prepared from non-immu-
nised rabbits. Puriﬁed mouse IgG2a (k chain) (MOPC-173)
control immunoglobulins were obtained from Pharmingen (San
Diego, CA, USA). Eukitt
1 mounting solution was from Poly Labo
Company (Strasbourg, France). All other chemicals were of analy-
tical grade and from Sigma Immuno Chemicals (Sigma-Aldrich
Corp., St Louis, MO, USA) or Merck (Darmstadt, Germany).
Cell culture and proliferation assay
B16 F10 cells were routinely grown in RPMI 1640, 2 mM gluta-
mine, 100 U ml
71 penicillin, 100 mgm l
71 streptomycin, and
10% FCS unless otherwise stated. Exponentially growing cells were
sparsly seeded (5000 cells per cm
2) in 96-multiwell plates in the
presence of 10% FCS. After 24 h when cell adhesion was achieved,
the medium was changed and the serum concentration set to 10, 5
or 2% FCS. SR 25989 was added at 37.5 and 150 mM. These two
concentrations were chosen as previous works have shown that
SR 25989 up to 37.5 mM had no effect on the proliferation of
human endothelial cells or skin ﬁbroblasts but displayed signiﬁcant
inhibitory activity in the range of 75–150 mM (Klein-Soyer et al,
1994, 1997). The medium was further changed at days 4 and 7
in identical conditions and the drug was added at each medium
change. At days 4, 7 and 10 representative samples were ﬁxed in
2% paraformaldehyde solution and B16 F10 proliferation was esti-
mated by quantiﬁcation of crystal violet staining of the cells with a
microplate reader (Gillies et al, 1986).
Clonogenic assay
The effects of SR 25989 on cell survival was investigated in a clono-
genic assay as follows: exponentially growing B16 F10 cells were
used for the experiments. Single cell suspensions were prepared
from B16 F10 cultures which had been submitted to increasing
concentrations of SR 25989 (0 to 400 mM) for 4 h in medium
containing 10% FCS. The suspensions were serially diluted in
medium containing 10% FCS and the different B16 F10 cell dilu-
tions were seeded in triplicate in 10 mm Petri dishes. After 7 to 10
days incubation without medium exchange, the cultures were care-
fully rinsed with PBS and stained with Giemsa dye and colonies
containing more than 50 cells (Brown and Wouters, 1999) were
counted to establish the survival curve.
Quantitative assay of angiogenesis in vitro
In vitro angiogenesis experiments were performed using the model
described by Nicosia and Ottinetti (1990) with slight modiﬁcations.
Male Wistar rats were anaesthetised with rompun/ketalar solution.
Prior to dissection of the thoracic aorta a bolus of hirudin
(3.5 mg kg
71 i.v.) was injected into the animal to inhibit any trace
of generated thrombin. The vessel was placed in survey medium
consisting of Hank’s balanced salt solution containing 1% HSA,
100 U ml
71 penicillin, 100 mgm l
71 streptomycin, 0.25 mgm l
71
fungizone. It was processed within 2 h following collection. The
aorta was carefully cleaned from surrounding ﬁbroadipose tissue
and extensively washed in survey medium containing 2.5 times
concentrated antibiotics and fungizone. Angiogenesis chambers
consisted of agarose rings with 11 mm inner diameter. Each agar-
ose ring was placed in one well from a six well dish. One
millimetre long aorta fragments were embedded in ﬁbrin gels
according to published procedures (Nicosia and Ottinetti, 1990)
as follows: the ﬁbrinogen solution (3 mg ml
71 in PBS without
Ca and Mg) was allowed to clot by adding a-thrombin (0.2 NIH
Um l
71 in 3 mM CaCl2 solution) the bottom of each agarose well
was coated with 100 ml of clotting ﬁbrinogen solution and the
ﬁbrin gel was allowed to polymerise at 378C. Then, the aorta rings
were transferred to the wells and positioned on top of the gelling
solution. The agarose wells was then ﬁlled with ﬁbrinogen clotting
solution. After polymerisation at 378C, serum-free culture medium
consisting in DMEM/HAM F12 supplemented with MgSO4
(10 mM ﬁnal), 100 U ml
71 penicillin, 100 mgm l
71 streptomycin
and 2.5 mgm l
71 fungizone, was added to each dish. In order to
prevent ﬁbrinolysis, e-amino caproı ¨c acid was added throughout
the experiments. The medium was changed every second day and
enumeration of newly formed vessels, arising from the intimal
endothelium and the vasa vasorum of the aorta rings, was
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(magniﬁcation 640, Nikon Diaphot TMD). Experiments in which
occasionally smooth muscle cells or ﬁbroblasts developed, recognis-
able because they formed cell layers instead of tubules, were
systematically discarded.
Effect of the thienopyridine SR 25989 on spontaneous
angiogenesis and angiogenesis induced by PDGF in vitro
SR 25989 in the range 1.5 to 150 mM was added to the culture
medium, starting from day zero and at every medium change.
The formation of neovessels was quantiﬁed according to criteria
described by Nicosia and Ottinetti (1990). In a second set of
experiments PDGF (1 ng ml
71) was added from time zero and
every second day until day 4. This growth factor presented to be
the most potent to induce angiogenesis in this model as compared
to bFGF (data not shown). Also, it had been shown previously that
ticlopidine, another member of the thienopyridine family inhibits
the release of PDGF from platelets (Morimoto et al, 1992). Due
to the difference in reactivity between individual animals the
number of spontaneously growing microvessels was heterogeneous
between separate experiments. Nevertheless, for a given experiment
this concentration of the growth factor was shown to enhance
spontaneous new capillary formation by up to 5–10 times over
control values in our system (unpublished observations). At day
4, when angiogenesis was well established, increasing concentra-
tions of SR 25989 were added once to culture medium and
neovascularization was quantiﬁed 24 h thereafter.
Experimental spontaneous lung metastasis model
Exponentially growing B16 F10 cells detached by brief exposure to
0.05% Trypsin/0.02% EDTA were washed twice in complete
medium and ﬁnally resuspended in Hank’s balanced salt solution.
A single suspension of cells (depending on the experiment, ﬁve to
8.5610
5 cells, in 100 ml) was injected into the foot pad of C57BL/6
mice. This model was chosen in order to observe the effect of the
drug on the development of the primary tumour and on the
grounds of the high vascularisation of the foot pad. This makes this
model closer to the ‘artiﬁcial pulmonary metastasis model’ which
requires injection of the tumour cells directly in the tail vein than
to the model implying implantation of tumour cells in the dorsal
subcutaneous space. The injection schedule systematically alter-
nated between mice in the control group and mice in the SR
25989 treated group to minimise differences which might be attrib-
uted to the duration of the injection protocole. At the end of the
inoculation procedure the viability of B16 F10 cells assessed by
Trypan blue dye exclusion was &85%. Animals were given either
SR 25989 50 mg kg
71 (equivalent to 120 mmoles kg
71) or normal
saline (control groups) intraperitoneally daily from the day of
tumour inoculation to the time of sacriﬁce. The animals were alert
throughout the experiment, did slowly gain weight during primary
tumour development and signiﬁcantly after amputation. The
tumour bearing foot was amputated at day 23. At this time the
mean tumour size reached 500 mm
3. At distance from amputation
one mouse from each series was sacriﬁced in order to assess the
presence of metastases. This allowed to determine the time of sacri-
ﬁce and autopsia before the development of metastases would
cause dyspnoea. The mice were sacriﬁced around day 40. The
tumours and inguinal lymph nodes were measured with a dial-
caliper and the volumes calculated using the following formula:
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Figure 1 Inhibition of angiogenesis in vitro by SR 25989. (A) Kinetics of
microvessels development as a function of SR 25989 concentration. Results
are the mean+s.e.m. of four independent experiments performed in tripli-
cates. (B) Number of microvessels as a function of increasing concentra-
tions of SR 25989. Results (expressed as a percentage of control values)
are the mean+s.e.m. of eight independent experiments with three angio-
genesis chambers per condition. *Signiﬁcantly different from control
(P50.05).
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Figure 2 Effect of SR 25989 on angiogenesis in vitro induced by PDGF.
PDGF (1 ng ml
71) was added to angiogenesis chambers until day 4. Then
increasing concentrations of SR 25989 were added once (arrow). Micro-
vessel formation was evaluated every day. Results are the mean+s.e.m.
of three separate experiments with three angiogenesis chambers per con-
dition. *Signiﬁcantly different from control (P50.05).
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26length60.52. The number and the size of metastatic foci
on the pulmonary surface were macroscopically quantiﬁed. The
primary tumour, inguinal lymph nodes and lungs were ﬁxed in
10% formalin solution and embedded in parafﬁn.
Immunohistochemistry
Parafﬁn-embedded tumours, inguinal lymph nodes and lung
sections were stained for vWf and for a-SMA by standard indirect
immunoperoxidase staining. Proteolytic predigestion of the forma-
lin ﬁxed tissue with 0.05% Trypsin for 30 min at room
temperature was performed prior to incubation with anti-vWf anti-
bodies. Primary antibodies were diluted according to the
manufacturer’s recommendations and the tissue sections were incu-
bated overnight at 48C. Control staining was carried out in each case
by replacing the primary antibody by matched isotypic non immune
immunoglobulins. Next, the samples were incubated with the
appropriate peroxidase conjugated secondary antibodies for 1 h at
room temperature. Tissue labelling was revealed by 3,3'-diamino-
benzidine staining, and the samples ﬁnally counterstained with
haematoxylin (Harris formula) and mounted in Eukitt
1.
Statistical analysis
The effects SR 25989 were compared by variance analysis followed
by the Neuman–Keuls test, using the statistical software STAT-
ITCF (ITCF, Boigneville, France).
RESULTS
Inhibition of spontaneous angiogenesis in vitro by the
thienopyridine SR 25989
The thienopyridine was added to angiogenesis chambers in serum-
free medium at the following concentrations: 37.5, 75 and 150 mM,
starting from day zero and at each medium change. As already
published (Nicosia and Ottinetti, 1990), the ﬁbrin gel stimulated
an angiogenic process and microvascular sprouts developed with
time. SR 25989 inhibited the formation of new vessels in a dose
dependent manner and inhibition was almost complete for the
higher concentration (Figure 1a). Evaluation of angiogenesis at
day 7 as a function of SR 25989 concentration showed that half
maximal inhibition was reached at less than 50 mM and was almost
complete for concentrations over 60 mM SR 25989 (Figure 1b).
Effects of SR 25989 on angiogenesis in vitro induced
by PDGF
PDGF (1 ng ml
71) was added starting from time zero of the
experiment. This concentration of the growth factor enhanced
the formation of spontaneous capillaries by 5 to 10 times over
control values in a given experiment. When neovascularization
was well established, at day 4, a low and a high concentration of
SR 25989 were added to the culture medium and angiogenesis
chambers incubated for one more day. When compared to the
controls devoid of thienopyridine, the low concentration of SR
25989 (15 mM) inhibited further increase of newly formed micro-
vessels (Figure 2) while the high concentration (150 mM)S R
25989 caused a total regression of the already established angio-
genesis with a complete disappearance of the capillaries, leaving
only dead isolated cells.
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Figure 3 B16 F10 cells proliferation in the presence of SR 25989. B16
F10 cells were grown in the presence of 37.5 or 150 mM SR 25989 in med-
ium containing 2, 5 or 10% FCS and proliferation estimated by colouri-
metric quantiﬁcation after Cristal Violet staining as described in Materials
and Methods. Results are the mean+s.e.m. of four independent experi-
ments performed in duplicates.
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Figure 4 Clonogenic survival of B16 F10 cells treated with SR 25989.
B16 F10 cells were exposed to increasing concentrations of the thieno-
pyridine as described in Materials and Methods. Colonies containing more
than 50 cells were counted at day 8. Mean+s.e.m. of one representative
experiment out of three performed in triplicates.
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The serum induced proliferation of B16 F10 cells was analysed in the
presence of SR 25989 used at two doses encompassing the range of
concentrations used in the preceding experiments. Control B16
F10 cells, as quantiﬁed by crystal violet staining of adherent cells,
proliferated exponentially up to day 7 in the presence of 5 and
10% FCS and up to day 10 with 2% FCS (Figure 3). The apparent
decrease in cell density observed at day 10 in the presence of 5
and 10% FCS was due to cell detachment caused by extremely high
cell density. As previously shown for human endothelial cells and
skin ﬁbroblasts (Klein-Soyer et al, 1994, 1997) the lower concentra-
tion (37.5 mM) did not signiﬁcantly affect B16 F10 cell proliferation
as compared to corresponding control cultures. In contrast, the
higher concentration (150 mM) totally inhibited the proliferation of
the cells cultivated in 2 and 5% FCS and inhibited by over 90%
the proliferation of B16 F10 cells cultivated in 10% FCS demonstrat-
ing cytostatic effects of this molecule in vitro (Figure 3).
Effects of SR 25989 on B16 F10 cells survival
In order to verify that SR 25989 should not have major toxic
effects for cells in the range of concentration used for proliferation
assays, the clonogenic survival of B16 F10 cells was analysed after
exposure for 4 h to increasing concentrations of SR 25989 (50 to
400 mM). Up to 150 mM, SR 25989 did not decrease B16 F10 cells
survival. For 200 mM the clonogenicity was only reduced by 20%
thereafter it decreased rapidly and dose dependently reaching less
than 5% for 400 mM (Figure 4).
SR 25989 does not affect the development of primary
tumours and inguinal lymph nodes
When B16 F10 cells were inoculated into the foot pad of C57BL/6
mice melanic marks appeared as soon as day 7 after injection.
Primary tumours developed equally in control and treated animals
and the tumour bearing foot was amputated when tumours
reached a mean volume of 500 mm
3. Although tumours from
the series treated with SR 25989 tended to develop at a lower rate
a few days prior to amputation the average volume attained at this
time was not signiﬁcantly smaller than in the control series (data
not shown). The overall vascularisation (macro and microvascular-
isation) as assessed by vWF and a-SMA staining, was not different
between the two series. The extent of necrotic areas, estimated on
Hematoxylin-Eosin stained sections seemed however to be slightly
larger in treated series although this difference did not appear to be
statistically signiﬁcant (data not shown). From the time of amputa-
tion most of animals developed inguinal lymphadenopathies at the
site of the tumour bearing foot. The frequency of appearance of
lymph nodes was similar between control and treated animals
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Figure 5 Inhibition of the development of pulmonary metastases by SR 25989. (A) The number and the size of macroscopic pulmonary metastases were
quantiﬁed at autopsia. Histogram left represents the mean of total maroscopic metastases. Histogram right represents the distribution of the metastases as a
function of their diameter. Results are the mean+s.e.m. for 11 control mice and 10 treated mice. One representative experiment out of three. (B) Parafﬁn
embedded lung sections, Hematoxylin-Eosin staining. Left:control lung showing numerous coalescent metastases. Right: treated lung showing small peri-
pheral or intrapulmonary metastases.
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volumes of the lymph nodes were not different (data not shown).
The health state of the mice was identical in control and SR 25989
treated mice although the weight gain was slightly but not signiﬁ-
cantly lower in the latter group. Again no signiﬁcant histological
difference could be observed between the two series (data not
shown).
Inhibition of the development of spontaneous pulmonary
metastasis by subcutaneously administered SR 25989
The average number of macroscopic pulmonary metastatic foci was
diminished by 33% in animals treated with SR 25989 (Figure 5A
left) when examined at the time of sacriﬁce. In addition when
the metastases were distributed as a function of their diameter, it
appeared that the size of the metastases was signiﬁcantly greater
in control animals and that most of the metastases from SR
25989 treated animals were classiﬁed in the category of smallest size
(Figure 5A right). Histological sections of lungs from control mice
showed large conﬂuent metastases invading the entire pulmonary
tissue and emerging at the surface of the lung while for SR
25989 treated mice the metastases remained signiﬁcantly smaller
and mainly localised at the pulmonary surface (Figure 5B). Immu-
nostaining with a speciﬁc antibody to a-SMA demonstrated that
most of the metastases initially formed cuffs around preexisting
vessels or obstructed vascular lumens (data not shown). Angiogen-
esis was analysed using antibodies to vWf, the speciﬁc marker of
endothelial cells. Normal preexisting vessels in the lung were
stained but neovascularisation was absent from small (52m m
diameter) metastases in both control and SR 25989 treated mice.
In larger metastases numerous new capillary sprouts essentially
located at the periphery of metastases were found in controls but
were totally absent in metastases of similar size from SR 25989
treated mice (Figure 6 left). Mature vascularisation visualised by
a-SMA staining appeared otherwise similar in the metastases from
control and SR 25989 treated animals (Figure 6 right).
DISCUSSION
The present results demonstrate that SR 25989, a member of the
thienopyridine family, which has previously been shown to display
anti-angiogenic properties in vitro (Klein-Soyer et al, 1994, 1997)
also inhibits the development of metastases through an anti-angio-
genic process in a murine pulmonary metastasis model.
Despite the availability of an ever-increasing number of potential
tumoral prognostic markers and the use of aggressive therapies the
prognosis of many cancer pathologies has to date only little been
improved. This underlines the crucial need for deﬁning new speci-
ﬁc criteria integrating the vast diversity of the tumoral genetic
alterations. One such strategy has since recent years been
approached through the means of angiogenesis for several reasons:
(i) the passage from normal tissue to hyperplasia and to tumori-
genesis is related to an angiogenic switch (Hanahan and
Folkman, 1996); (ii) angiogenesis is a dynamic balance between
stimulators and inhibitors (Hanahan and Folkman, 1996; Iruela-
Arispe and Dvorak, 1997). In the absence of angiogenesis the
balance is in favour of the inhibitors which as such can account
for tumour and micrometastases ‘dormancy’ (Folkman, 1995a;
Holmgren et al, 1995); (iii) Due to its speciﬁc characteristics, the
tumour vasculature constitutes a common feature between the
various tumoral tissues (Denekamp et al, 1998). These data have
opened an extensive ﬁeld of investigation to ﬁnd new anti-angio-
genic molecules. Among these molecules the thienopyridine
ticlopidine has been shown to reduce the progression of non prolif-
erative diabetic retinopathy (TIMAD Study Group, 1990;
Guillausseau, 1994) and to inhibit pulmonary metastasis develop-
ment in mice (Kohga et al, 1981; Bando et al, 1984). These
results prompted us to evaluate the potential anti-angiogenic prop-
erties of another member of the thienopyridine family SR 25989
which is an enantiomer of the anti-aggregant clopidogrel (Plavix)
but which lacks anti-aggregant activity.
We have previously shown that SR 25989 inhibited spontaneous
and growth factor induced endothelial cell migration and prolifera-
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Original magnification ´200
Figure 6 Representative immunohistochemistry of pulmonary metastases from control and SR 25989 treated mice. Parafﬁn embedded lung sections
were labelled with anti-von Willebrand factor antibody (vWf) or anti-a-Smooth muscle actin antibody (a-SMA) as described in Materials and Methods.
An intense labelling for vWf can be seen in a metastase from a control lung (upper left), this labelling is totally absent in a metastase of identical size from
a treated lung (lower left). a-SMA labelling in the metastases from adjacent sections of the lungs from control and treated mice (right).
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Now, the quantitative angiogenesis assay (Nicosia and Ottinetti,
1990) allowed to further assess the anti-angiogenic properties of
the thienopyridine in vitro: (i) SR 25989 inhibited in a dose depen-
dent manner the spontaneous microvessel formation from rat aorta
fragments embedded in a ﬁbrin gel; (ii) It caused the regression of
microvessel development induced by the growth factor PDGF.
Hence, we went on evaluating the anti-angiogenic effects of this
thienopyridine in a murine pulmonary metastasis model.
High concentrations of SR 25989 displayed cytotoxic effects on
the proliferation of B16 F10 cells in vitro, however it apparantly
did not signiﬁcantly affect the development of the primary tumour
at the therapeutic doses assayed in mice as far as the size of the
tumour was considered. For principles of animal care and comfort
it was not possible to fully analyse the slight inhibitory effect
observed on SR 25989 treated tumour right before amputation.
That SR 25989, which potentially inhibits angiogenesis, did not
alter tumour growth and lymph node development can be
explained by the high vascularisation of the foot pad. This site of
injection has been chosen on this purpose to favour tumour cell
shedding in the circulation thus allowing distant metastasis devel-
opment. The already existing vascularisation may be sufﬁcient to
explain the regular growth of primary tumours and development
of proximal lymph nodes perhaps by vessel cooption (Holash et
al, 1999). Alternatively, considering the initially high number of
tumour cells injected in the foot pad and subsequently isolated
tumour cells shed in the circulation, the balance between angiogen-
esis activators and inhibitors may have been different in the
primary tumour and in developing metastases. Thus the available
concentration of SR 25989 could have been insufﬁcient to efﬁ-
ciently inhibit angiogenesis activators participating to primary
tumour development. Although the thienopyridine did not signiﬁ-
cantly hinder primary tumour growth, a striking effect of SR 25989
could be observed on the development of pulmonary metastases.
Both the number and the size of the metastases were reduced in
animals treated with the thienopyridine. While in lungs from
control animals numerous coalescent metastases were observed,
the lungs from SR 25989 treated animals contained only few metas-
tases and these were signiﬁcantly smaller. In large metastases from
control mice immature vascularisation could be vizualized by vWf
immunostaining. This type of labelling was always absent in lung
sections from SR 25989 treated animal. This reinforces the fact that
SR 25989 inhibits distant metastasis development through an anti-
angiogenic process. Such a paradoxical effect in which an angio-
genesis inhibitor has no effect on primary tumour growth but a
dramatic effect on metastases development seems not to be seldom
and has also very recently been reported for the avb3 integrin
antagonist S-247 (Griggs et al, 2001). It has been shown in preli-
minary experiments that 50 mg kg day
71 of SR 25989 given
orally to the rat using the model of ﬁbrin gel chambers implanted
in the subcutaneous dorsal space of the rat as described by Dvorak
et al (1987), that SR 25989 signiﬁcantly inhibits the development of
capillaries within the ﬁbrin gel (Cazenave and Herbert, 1992; Toti
et al, 2001). The dose of SR 25989 that we used here is within the
range used for other angiogenesis inhibitors such as TNP-470
(30 mg kg day
71) (Gervaz et al, 2000) AG3340 (100 mg kg
71
daily) (Shalinsky et al, 1999), ZD6474 (7.5 to 30 mg kg day
71)
(Wedge et al, 2001) or angiostatin and endostatin (20 mg kg
71
daily) (Lush et al, 1999). It did not otherwise signiﬁcantly alter
the health and the survival of the mice nor induce any speciﬁc
secondary effect as compared to control mice treated with normal
saline.
Previous results from our laboratory suggest that the anti-angio-
genic effects of SR 25989 could possibly be related to an
upregulation of endogenous TSP-1 (Klein-Soyer et al, 1997). This
matricellular glycoprotein is a complex protein displaying multiple
functions mediated by interactions through identiﬁed domains
with a wide range of matrix proteins and cell surface receptors
(Bornstein, 1995). TSP-1 regulates tumour growth and metastasis
development through an anti-angiogenic process (Roberts, 1996;
DiPietro, 1997). Its involvement in anti-angiogenic processes seems
to proceed through different mechanisms in particular by inducing
endothelial apoptosis through a caspase pathway (Nor et al, 2000)
or by acting as a ‘molecular bridge’ in adhesion complexes invol-
ving integrins such as av b3 (Savill et al, 1992; Luscinskas and
Lawler, 1994) thus reducing the adhesive contacts between cells
and extracellular matrix (Sage and Bornstein, 1991). Recently, an
upregulation of TSP-1 has been observed in murine mammary
carcinoma after intratumoral injection of endostatin plasmid,
which itself is known as an angiogenesis inhibitor (Ding et al,
2001). For all these reasons TSP-1 appears now among the most
relevant endogenous inhibitors of angiogenesis.
The thienopyridine SR 25989 inhibits metastatic dissemination
and growth through an anti-angiogenic process possibly by up-
regulating the endogenous angiogenesis inhibitor TSP-1. SR
25989 seems to show valuable anti-angiogenic effects both in vitro
and in vivo and thus deserves further evaluation in view of its
potential use as an adjuvant treatment of cancer therapy in
humans.
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